UCI 趙 Chao Family Comprehensive Cancer Center

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Managers:
Stephanie Osorio
Judit Castellanos

Clinical Research Coordinators:
Alice Ting
Michael Kunicki
Kelsey McAbee
Georgina Alvarez-Diaz
Melisa Duvnjak
Makena Castillo
Cristian Franco

Data Coordinators:
Heather Franson
Mario Diaz
Sarahy Martinez

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Myeloproliferative Neoplasm

UCI 24-121
ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 4/5

Coord: Georgina Alvarez-Diaz

UCI 26-12 (NEW)
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Accrual:0
Coord: TBA

UCI 20-50
N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 15/27

Coord: Kelsey McAbee

ETCTN 10675
A Randomized Phase II Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

Myelodysplastic Syndrome

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Low-Risk

Molecularly-Driven

HSCT

High-Risk

MM1MDS-A01
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

UCI 24-121
ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 4/5

Coord: Georgina Alvarez-Diaz

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Low-Risk

UCI 21-239
IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual: 2/5

Coord: Georgina Alvarez-Diaz

Molecularly-Driven

High-Risk

UCI 25-193
ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 0/7

Coord: Georgina Alvarez-Diaz

Myelodysplastic Syndrome

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Intensive

ETCTN-10596
SNDX-5613 + Daunorubicin and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia (NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged)

Accrual: 0/5

Coord: TBA

MYELOMATCH
MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Accrual: 0/5

Coord: Makena Belle Castillo

Non-Intensive

ETCTN-10630 (Suspended)
Ladademstat in Combination with Venetoclax and Azacitidine in Patients with Post MDS Transformation to AML

Accrual: 2/7

Coord: TBA

UCI 24-121
ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 4/5

Coord: Georgina Alvarez-Diaz

UCI 22-81
HM43239 in patients w/ R/R AML
Accrual: 3/6

Coord: Georgina Alvarez-Diaz

KMT2A-r/NPM1-m

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 9/10

Coord: Georgina Alvarez-Diaz

FLT3 mutation

UCI 21-216 (suspended)
Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 2/5

Coord: TBA

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Non-Intensive

UCI 25-166

An Open-label Phase 3 Study Evaluating the Efficacy and Safety of QTX-2101 in Newly Diagnosed Acute Promyelocytic Leukemia

Accrual: 0/5
Coord: TBA

KMT2A-r/NPM1-m

UCI 25-20
Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged AML

Accrual: 3/5

Coord: Georgina Alvarez-Diaz

IDH1-R132-m

UCI 25-90
Olutasidenib in Combination with Azacitidine Followed by Olutasidenib Maintenance After Venetoclax Plus a Hypomethylating Agent Regimen (HMA-VEN) for IDH1-Mutated Acute Myeloid Leukemia (AML)
Accrual: 0/5

Coord: TBA

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

2nd+ Line

UCI 22-81
HM43239 in patients w/ R/R AML
Accrual: 3/6
Coord: Georgina Alvarez-Diaz

2nd Line Only

UCI 25-105 (NEW)
LYT-200 in patients w/ R/R AML or high-risk MDS
Accrual: 0/5
Coord: TBA

Non-Intensive

UCI 25-193
ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies
Accrual: 0/7
Coord: Georgina Diaz

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 9/10

Coord: Georgina Alvarez-Diaz

KMT2A-r/NPM1-m

UCI 23-154
Ziftomenib combinations for the KMT2A-rearranged/NPM1 mutant R/R AML

Accrual: 3/5

Coord: Georgina Alvarez-Diaz

Maintenance

High-Risk, HSCT

Salvage Therapy

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

Age ≥ 60 years or <60 if non-intensive CD19+ (≥ 20% lymphoblasts)

SWOG-21CTP-LEUK01
Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Dx Ph+ B-ALL

Accrual: 1/5
Coord: Makena Belle Castillo

Age ≥ 75 years or >18 if non-intensive CD22+ (≥ 20% lymphoblasts)

A041703: Cohort 3
Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage ALL in Newly Diagnosed Older Adults or Adults with R/R Disease
Accrual: 2/5

Coord: Makena Belle Castillo

Ph- only

Age ≥ 18 years & < 40 years CD22+ (≥ 20% lymphoblasts)

A041501
Addition of Inotuzumab Ozogamicin to frontline therapy in young adults (18-39y/o)

Accrual: 10/15

Coord: Makena Belle Castillo

Age ≥ 18 years

UCI 25-104 (NEW)
subcutaneous blinatumomab vs. intravenous blinatumomab in newly diagnosed adults with (Ph)- B cell precursor ALL

Accrual: 0/5

Coord: TBD

Age ≥ 60 years CD22+ (≥ 20% lymphoblasts)

A041703: Cohort 1
Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage ALL in Newly Diagnosed Older Adults or Adults with R/R Disease
Accrual: 2/5

Coord: Makena Belle Castillo

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

Ph- only

Age ≥ 12 years CD19+

26-53 (New)
A PhII/III Randomized, Open-Label, Comparison Study of MK-1045 vs Blinatumomab in patients with R/R CD19+ B-ALL

Accrual:0/5

Coord: TBD

Age ≥ 18 years CD22+

UCI 25-209 (NEW)
UCART22 (allogeneic Anti-CD22 CAR-T) in R/R CD22+ B-ALL

Accrual: 0/3

Coord: TBD

Age ≥ 18 years CD22+ (≥ 20% lymphoblasts)

A041703: Cohort 2
Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage ALL in Newly Diagnosed Older Adults or Adults with R/R Disease
Accrual: 2/5

Coord: Makena Belle Castillo

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 25-166 (NEW)

An Open-label Phase 3 Study Evaluating the Efficacy and Safety of QTX-2101 in Newly Diagnosed Acute Promyelocytic Leukemia

Accrual: 0/5
Coord: TBA

Hemophagocytic Lymphohistiocytosis

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 23-189
Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 1/6

Coord: TBA

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd+ Line

UCI 23-167
Phase I- TERN-701 in patients w/CML

Accrual: 2/5

Coord: Kelsey McAbee

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

Front Line

2nd+ Line

UCI 26-101 (NEW)
ASC4REAL-2: A real-world chronic myelogenous leukemia (CML) patient disease registry to describe patient experience and clinical outcomes among patients with CML receiving approved first or second line tyrosine kinase inhibitor (TKI) therapy

Accrual: 0/11

Coord: TBA

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

SWOG-S2213
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Accrual: 0/5
CRC: Alice Ting

UCI 26-116 (NEW)

A Randomized Phase 3 Study to evaluate the efficacy and safety of NXC-201 compared with Daratumumab with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]

Accrual: 0/3

Coord: TBA

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Anti-BCMA

UCI 23-158
Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma
Accrual: 2/6 (opened 3/29/24)
Coord: Alice Ting

BsAbs

UCI 26-69 (NEW)
Sequential integration of bispecific monoclonal antibodies into Treatment of Newly Diagnosed Multiple Myeloma

Accrual: TBA

Coord: TBA

CAR-T

UCI 25-220 (NEW)
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120 Compared with Continuous Standard Therapy in Participants with NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

Coord: TBA

UCI 25-221 (NEW)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment with AZD0120 vs ASCT, in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible

Accrual: TBA

Coord: TBA

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

≥ 1-3 prior lines

UCI 26-07
Phase 3 Randomized Study Comparing JNJ-79635322 vs. Teclistamab in Participants with R/R MM who Have Received 1-3 Prior Lines of Therapy

Accrual: 0/5
Coord: TBA

UCI 26-33
Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) For Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Accrual: 0/7
Coord: Alice Ting

≥ 2 prior lines

UCI 26-52
A Phase IB, Multi-center, study of talquetamab in combination with iderdomide and Dexamethasone for the treatment of Relapsed or Refractory Multiple Myeloma
Accrual: 0/5
Coord: TBD

≥ 3 prior lines

UCI 25-116
A Phase I Antitumor Activity of SIM0500, A Humanized GPTC5D-BCMA-CD3 Trispecific Antibody, in Participants with R/R MM
Accrual: 0/3
Coord: Alice Ting

UCI 26-07
Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma who Have Received 1-3 Prior Lines of Therapy

Accrual: 0/5
Coord: TBA

Maintenance

ALLIANCE-A062102
Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in R/R MM
Accrual: 0/5
Coord: Michael Kunicki

CAR-T

UCI 25-62 (NEW)
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Nonconforming for Commercial Release
Accrual: 0/5
Coord: Michael Kunicki

Multiple Myeloma

Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

Supportive Care

UCI 24-170
Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Pts With MM Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy
Accrual: 0/10

Coord: Alice Ting

UCI 26-51
A Phase 3, Prospective, Open-label multicenter, single-arm study to investigate the efficacy, safety and pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic

Accrual: TBD
Coord: TBD

Diffuse Large B-Cell Lymphoma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 23-19
PhIII Odronextamab Comb w/CHOP vs Rituximab Comb w/CHOP

Accrual: 0/5
Coord: Melisa Duvnjak

26-59 (New)
A Phase III study to Evaluate The Efficacy of Surovatamig Combined with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-Chop) in previously untreated Large B-Cell Lymphoma

Accrual: 0/3

Coord: TBD

UCI 24-22
Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-risk Diffuse Large B-cell Lymphoma
Accrual: 0/1

Coord: Melissa Duvnjak

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

Coord: Melisa Duvnjak

Diffuse Large B-Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Tertiary Relapsed/Refractory

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 1/6

Coord: Michael Kunicki

2+ Lines

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 9/10

Coord: Michael Kunicki

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

Coord: Melisa Duvnjak

26-64 (New)
A randomized, Open Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

Coord: TBD

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Low Grade

SWOG S2308
Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Accrual: 1/5

Coord: Melisa Duvnjak

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

3rd Line+

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 1/6

Coord: Michael Kunicki

Maintenance

UCI 21-95
Acalabrutinib Maintenance Following Cellular Therapy for LBCL Patients at High Risk for Relapse

Accrual: 0/5

Coord: Michael Kunicki

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

TF FL or FL Grade 3B

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL
Accrual: 9/10
Coord: Michael Kunicki

UCI 25-70
Ph III of LYL314 in 2L for R/R B-Cell NHL
Accrual: 0/7
Coord: Michael K.

On-label & Nonconforming

UCI 25-63
EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release
Accrual: TBD
Coord: Michael Kunicki

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

3rd Line+

3rd+ Line

UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

Mantle Cell Lymphoma

Marginal Zone Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

EBV+ | Molecularly-Driven

3rd Line+

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

High-Risk

S1925
Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 5/10

Coord: Kelsey McAbee

Front Line

UCI 25-192 (NEW)
Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patient with Previously Untreated CLL

Accrual: 0/7

Coord: TBA

S2504 (NEW)
A Randomized Phase III Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Participants with Previously Untreated Richter Transformation (pirAMID)

Accrual: 0/5

Coord: TBA

Follow Up

UCI 25-205 (NEW)
Long-term follow-up of ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL

Accrual: 0/6

Coord: TBA

Chronic Lymphocytic Leukemia

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Chronic Lymphocytic Leukemia

2nd+ Line

UCI 24-190
A Phase III Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax + Rituximab in Patients With R/R CLL/SLL

Accrual: 1/7

Coord: Kelsey McAbee

UCI 24-32
Epcoritamab as Consolidation Therapy for High-risk Patients with Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor

Accrual: 0/24

Coord: Kelsey McAbee

UCI 26-65 (NEW)
Study of Surovatamig as Consolidation Therapy versus Observation after First-line Induction Therapy in Participants with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with Unmutated IGHV (SOUNDTRACK-C1)
Accrual: TBD
Coord: TBD

3rd+ Line

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

UCI 26-36 (NEW)
Phase 2 Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) (CLL) or (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
Accrual: 0/5

Coord: TBD

UCI 26-84 (NEW)
Phase 2 study of MK-1045 in Participants with Hematologic Malignancies
Accrual: TBD

Coord: TBD

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

2+ Lines

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 1/6

Coord: Michael Kunicki

26-64 (NEW)
A randomized, Open Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

Coord: TBD

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2+ Lines

Molecularly-Driven

Cell Therapy

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 9/10

Coord: Michael Kunicki

3rd line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

Coord: Melisa Duvnjak

UCI 24-174
Efficacy and Safety of ITK Inhibitor Soquelitinib Vs Physician's Choice SOC Treatment (Selected Single Agent) in R/R Peripheral T-cell Lymphoma, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 1/5

Coord: Melisa Duvnjak

UCI 21-95
Acalabrutinib Maintenance Following Cellular Therapy for LBCL Patients at High Risk for Relapse

Accrual: 0/5

Coord: Michael Kunicki

Waldenstrom's Macroglobulinemia & Other NHL Subtypes

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 21-99
ONO-4685 given as monotherapy

Accrual: 5/10

Coord: Melisa Duvnjak

UCI 25-74 (Reopened)
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 3/5

Coord: Melisa Duvnjak

2nd Line+

UCI 25-142
Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: TBD

Peripheral T-Cell Lymphoma

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Treatment-Naive

UCI 22-18
Investigation of MRD in patients with treatment-naive systemic T cell lymphoma tx w/ a brentuximab-containing regimen

Accrual: 0/5

Coord: TBD

Post-Induction Treatment

ECOG EA4232
Phase III Study to Evaluate ASCT in Patients with PTCL that Achieved a First CR1 Following Induction Therapy (PTCL-STAT)

Accrual: 0/5

Coord: TBD

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Peripheral T-Cell Lymphoma

	R/R		
	1st Line +	2nd Line +	3rd Line +

UCI 24-174
ITK Inhibitor Soquelitinib vs. MD Choice SOC Tx in Participants w/ R/R PTCL NOS, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 1/5

Coord: Melisa Duvnjak

UCI 25-142
Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: TBD

UCI 21-99
ONO-4685 given as monotherapy

Accrual: 5/10

Coord: Melisa Duvnjak

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

	R/R		
	1st Line +	2nd Line +	3rd Line +

UCI 25-74

Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety & Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 3/5

Coord: Melisa Duvnjak

Cytotoxic Lymphomas

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

COG-AHOD2131
Standard Therapy with Immuno-oncology Therapy for Newly Diagnosed Stage I and II Classical Hodgkin Lymphoma

Accrual: 2/5

Coord: Melisa Duvnjak

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Basket study

2nd Line Only

UCI 25-21 (NEW)
Pembrolizumab and GVD with ctDNA-guided Consolidation in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma

Accrual: 0/5

Coord: TBA

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

Coord: Melisa Duvnjak

Non-Hodgkin's Lymphoma

HSCT and Cellular Therapy

CAR-T Products

Open to Accrual | Low Accruing | Pending Activation/Suspended

Allogeneic

NHL

ALL

UCI 25-209 (NEW)
UCART22 (allogeneic Anti-CD22 CAR-T) in R/R CD22+ B-ALL

Accrual: 0/3

Coord: TBA

Autologous

NHL

UCI 23-114
Safety & Efficacy of LYL314, a CD19/20 Bispecific CAR-T for R/R B-Cell NHL

Accrual: 9/10

Coord: Michael K.

UCI 25-63
EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: TBA

Coord: Michael K.

MM

UCI 25-62
EAP for Vicleucel (ide-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

Coord: Michael K.

UCI 25-220 (NEW)
AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

Coord: TBA

UCI 25-221 (NEW)
AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are ASCT Eligible

Accrual: TBA

Coord: TBA

CAR-T Products

Open to Accrual | Low Accruing | Pending Activation/Suspended

Allogeneic

NHL

ALL

Autologous

NHL

AL

UCI 26-116 (NEW)

A Randomized Phase 3 Study to evaluate the efficacy and safety of NXC-201 compared with Daratumumab with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]

Accrual: 0/3

Coord: TBA

MM

UCI 24-62

Ph III GPRC5D-directed CAR T Cell Therapy in Pts w/ R/R &Lenalidomide-exposed MM (QUINTESSENTIAL-2)

Accrual: 2/5

Coord: Michael K.

Supportive Care

Open to Accrual | Low Accruing | Pending Activation/Suspended

Autologous

UCI 23-193
CTO1681 for the Prevention & Treatment of CRS in pts w/ DLBCL receiving CAR-T Therapy

Accrual: 1/5

Coord: Michael K.

Alliance-A062102
Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

Coord: Michael K.

S2114
Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 1/6

Coord: Michael K.

UCI 24-110
HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical Hematopoietic Stem Cell Transplantation

Accrual: 0/7

Coord: Mario Diaz

Allogeneic

UCI 21-90
Risk-ADAPTed conditioning regimen for AHSCT

Accrual: 34/48

Coord: Mario Diaz

UCI 22-188
Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHCT

Accrual: 24/50

Coord: Mario Diaz

UCI 24-131 (Suspended)
Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Accrual: 0/5

Coord: Mike K.

UCI 25-139 (NEW)
Efficacy of SER-155 to Reduce Bloodstream Infections in Adults Undergoing Allogeneic HCT

Accrual: 0/5

Coord: TBD

LTFU

Open to Accrual | Low Accruing | Pending Activation/Suspended

Autologous

UCI 21-184
Long-term safety of CAR-T inpatient w/ heme malignancies

Accrual: 7/7

Coord: Michael Kunicki

UCI 26-30
UCHMC Review of Neurocognitive Deficits After CAR-T Therapy

Accrual: TBD

Coord: TBD

Allogeneic

UCI 24-110
HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical Hematopoietic Stem Cell Transplantation

Accrual: 0/7

Coord: Mario Diaz

UCI 26-86 (NEW)
A multicenter, prospective observational cohort study in US transplant centers

Accrual: 0/30

Coord: TBD

Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 14-89
Hematologic Malignancies Biorepository for human research

Accrual: 322/500

Coord: Helen Huang

UCI 22-194
A Retrospective analysis of L-carnitine for Treatment and/or Prevention of L-Asparaginase Hepatotoxicity during Induction or Salvage Chemotherapy for Hematologic Malignancies
Accrual: TBA
Coord: TBD

UCI 24-05
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical
Trial Accrual: 26/59
Coord: TBD

UCI 25-195
Clinical utility Karius testing for diagnosis & management of suspected infections in adult immunocompromised patients
Accrual: 0/10
Coord: TBD

UCI 25-198 (NEW)
A multicenter protocol for haploidentical stem cell transplantation: Optimization of transplant outcomes in a collaborative consortium
Accrual: TBD
Coord: TBD

UCI 25-226 (NEW)
Prospective Observational International Registry of Patients with Newly Diagnosed Burkitt Lymphoma
Accrual: 0/5
Coord: TBD

UCI 26-51 (NEW)
A Phase 3, Prospective, Open-label, Multicenter, Single-arm study to investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic Malignancies Treated with B-cell Depleting Therapies
Accrual: TBD
Coord: TBD

Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 25-48
RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)
Trial Accrual: 6/20
Coord: TBD

UCI 25-127 (NEW)
Biofield Therapy (Reiki) for fatigue- for patients receiving immunotherapy and experiencing **fatigue**
Accrual: TBD
Coord: TBD